Renal cell carcinoma: review decision - December 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 62 KB)
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 62 KB)
-
TA178 Renal cell carcinoma: review decision - May 2012 information
-
TA178 Renal cell carcinoma: review proposal - March 2012 information
-
Appendix A: provisional matrix of stakeholders
-
Appendix A: provisional matrix of stakeholders (MSWord 62 KB)
-
Appendix B: proposal paper presented to the Institute's guidance executive
-
Appendix B: proposal paper presented to the Institute's guidance executive (PDF 179 KB)
-
NICE issues guidance on the use of other treatment options for renal cancer (PDF 33 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal information
-
-
-
Roche
-
Roche: appeals received
-
-
Roche: initial scrutiny letter
-
-
Roche: response to scrutiny letter
-
-
Roche: final scrutiny letter
-
-
Wyeth
-
Wyeth: appeals received
-
-
Wyeth: initial scrutiny letter
-
-
Wyeth: response to scrutiny letter
-
-
Wyeth: final scrutiny letter
-
-
Wyeth: clarification letter
-
-
Wyeth: response to clarification letter
-
-
James Whale Fund for Kidney Cancer
-
James Whale Fund for Kidney Cancer: appeals received
-
James Whale Fund for Kidney Cancer: appeals received (PDF 66 KB)
-
James Whale Fund for Kidney Cancer: initial scrutiny letter
-
James Whale Fund for Kidney Cancer: initial scrutiny letter (PDF 26 KB)
-
James Whale Fund for Kidney Cancer: response to scrutiny letter
-
James Whale Fund for Kidney Cancer: response to scrutiny letter (PDF 105 KB)
-
James Whale Fund for Kidney Cancer: final scrutiny letter
-
James Whale Fund for Kidney Cancer: final scrutiny letter (PDF 16 KB)
-
Rarer Cancers Forum and Macmillan Cancer Support
-
Rarer Cancers Forum and Macmillan Cancer Support: appeals received
-
Rarer Cancers Forum and Macmillan Cancer Support: appeals received (PDF 46 KB)
-
Rarer Cancers Forum and Macmillan Cancer Support: initial scrutiny letter
-
Rarer Cancers Forum and Macmillan Cancer Support: initial scrutiny letter (PDF 27 KB)
-
Rarer Cancers Forum and Macmillan Cancer Support: response to scrutiny letter
-
Rarer Cancers Forum and Macmillan Cancer Support: response to scrutiny letter (PDF 17 KB)
-
Rarer Cancers Forum and Macmillan Cancer Support: final scrutiny letter
-
Rarer Cancers Forum and Macmillan Cancer Support: final scrutiny letter (PDF 18 KB)
-
Renal cell carcinoma: appeal decision
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination
-
-
Response to consultee, commentator and public comments on the first ACD and comments from website consultation
-
-
Response to consultee, commentator and public comments on the second ACD and comments from website consultation
-
-
Consultee and commentator comments on the ACD
-
Bayer
-
-
Department of Health
-
-
Macmillan and Rarer Cancers forum
-
-
NHS Quality Improvement Scotland
-
-
Roche
-
-
Royal College of Nursing
-
-
Wyeth
-
-
Expert comments on the ACD
-
David Chao
-
-
Bill Savage
-
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination
-
-
-
-
Update on renal cell carcinoma drugs
-
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
-
Consultee and commentator comments on the first ACD
-
Bayer
-
-
British Uro-oncology Group (BUG)
-
-
Cancer Research UK
-
-
Kidney cancer UK/James Whale fund for kidney cancer
-
Kidney cancer UK/James Whale fund for kidney cancer (PDF 70 KB)
-
Macmillan and Rarer Cancers Forum
-
-
National Kidney Federation
-
-
NHS Cambridgeshire
-
-
NHS Quality Improvement Scotland
-
-
Novartis
-
-
Pfizer
-
-
Royal College of Physicians
-
-
Roche
-
-
Welsh Assembly Government
-
-
Wyeth
-
-
Wyeth 2
-
-
External expert comments on the appraisal consultation document
-
Dr David Chao
-
-
Patient expert
-
-
Bill Savage
-
-
Report to the Appraisal Committee summarising comments (received by letter and email) on the appraisal consultation document - prepared by the Patient and Public Involvement Programme (PPIP) and Enquiry Handling team, September 2008
-
-
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic and economic evaluation - addendum to the report submitted on 2 May 2008 - prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter
-
-
Extra work on bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma - prepared by Decision Support Unit
-
-
First appraisal consultation document
-
-
Response from the Assessment Group to comments on the Assessment report
-
Response from the Assessment Group to comments on the Assessment report (PDF 210 KB)
-
Consultee and commentator comments on the extra work consultation
-
Bayer
-
-
British Uro-oncology Group
-
-
Novartis
-
-
Pfizer
-
-
Roche
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Wyeth
-
-
Extra work done by the Assessment Group (PenTAG) and the Decision Support Unit (DSU) on new data received
-
-
External expert comments received on the extra work consultation
-
Pat Hanlon
-
-
Dr David Chao
-
-
Bill Savage
-
-
Response from the DSU to comments on the extra work consultation
-
Response from the DSU to comments on the extra work consultation (PDF 16 KB)
-
Revised analyses submitted by Bayer incorporating the sorafenib patient access scheme and new price of sorafenib
-
-
Extra work done by the DSU on the revised analyses submitted by Bayer
-
Extra work done by the DSU on the revised analyses submitted by Bayer (PDF 54 KB)
-
Department of Health approval for the Technology Appraisal Committee to consider patient access schemes submitted for sorafenib and sunitinib
-
Department of Health approval of sunitinib patient access scheme
-
Department of Health approval of sunitinib patient access scheme (PDF 25 KB)
-
Department of Health approval of patient access scheme for sorafenib
-
Department of Health approval of patient access scheme for sorafenib (PDF 24 KB)
-
Consultee and commentator comments on the executable economic model
-
Pfizer
-
-
Bayer
-
-
DSU addendum to the review of Roche's request for parameter changes
-
DSU addendum to the review of Roche's request for parameter changes (PDF 17 KB)
-
Addendum to the pre-meeting briefing: end of life - a quantitative exploration
-
Addendum to the pre-meeting briefing: end of life - a quantitative exploration (PDF 16 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
-
Renal cell carcinoma - sunitinib: assessment report
-
Renal cell carcinoma - sunitinib: assessment report (PDF 1.82 MB)
-
Overview
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: consultee and commentator comments on the assessment report
-
Bayer
-
-
Kidney Research UK
-
-
NHS Quality Improvement Scotland
-
-
Pfizer
-
-
Pfizer 1
-
-
Pfizer 2
-
-
Roche
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Wyeth
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: non-manufacturer submission
-
Cancer Backup
-
-
National Kidney Federation
-
-
Joint submission from Kidney Cancer UK and James Whale Fund for Kidney Cancer
-
Joint submission from Kidney Cancer UK and James Whale Fund for Kidney Cancer (PDF 48 KB)
-
Joint submission from NCRI Renal Clinical Studies Group/Royal College of Radiologists/Royal College of Physicians/Joint Collegiate Council for Oncology/Association of Cancer Physicians
-
-
Kidney Research UK
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: manufacturer submissions (executive summary only)
-
Bayer
-
-
Pfizer
-
-
Pfizer - addendum to submission
-
-
Roche
-
-
Wyeth
-
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: expert written personal statements
-
Chao
-
-
Hanlon
-
-
Savage
-
-
Patient Expert Statement
-
Response to comments on pre referral remit and scope for STA sorafenib tosylate for advanced renal cell carcinoma
-
Response to comments on pre referral remit and scope for STA sorafenib tosylate for advanced renal cell carcinoma
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)
Response to comments on pre referral remit and scope for STA bevacizumab for metastatic renal cell carcinoma
-
Response to comments on pre referral remit and scope for STA bevacizumab for metastatic renal cell carcinoma
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix (PDF 48 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: response to consultee and commentators comments on the scope
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: response to consultee and commentators comments on the scope
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix
-
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix
-
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix (PDF 50 KB)
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope
-
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope
-
Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope (PDF 37 KB)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol
-
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol
-